These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26107645)

  • 1. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
    Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
    PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R; Dandara C; Viljoen M; Rheeders M
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
    Ngayo MO; Oluka M; Kwena ZA; Bulimo WD; Okalebo FA
    PLoS One; 2022; 17(3):e0260872. PubMed ID: 35235559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
    Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of efavirenz and frequency of the CYP2B6 516G>T polymorphism in people living with HIV-1 in Mexico.
    Ortíz-Rodríguez MA; Oaxaca-Navarro J; Patiño-Camacho SI; García-Jiménez S; Déciga-Campos M; Martínez-Salazar MF
    Pharmazie; 2022 Jun; 77(6):191-195. PubMed ID: 35751161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
    Sukasem C; Cressey TR; Prapaithong P; Tawon Y; Pasomsub E; Srichunrusami C; Jantararoungtong T; Lallement M; Chantratita W
    Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
    Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
    J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
    Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F
    Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele.
    Bordin Andriguetti N; Van Schalkwyk HK; Barratt DT; Tucci J; Pumuye P; Somogyi AA
    Clin Transl Sci; 2021 Nov; 14(6):2521-2531. PubMed ID: 34415664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
    Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
    Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
    Viljoen M; Karlsson MO; Meyers TM; Gous H; Dandara C; Rheeders M
    Eur J Clin Pharmacol; 2012 Apr; 68(4):339-47. PubMed ID: 22057858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
    Aurpibul L; Chotirosniramit N; Sugandhavesa P; Kosashunhanan N; Thetket S; Supindham T; Piyamongkol W; Supparatpinyo K
    Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
    Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.
    Vujkovic M; Bellamy SL; Zuppa AF; Gastonguay M; Moorthy GS; Ratshaa BR; Han X; Steenhoff AP; Mosepele M; Strom BL; Aplenc R; Bisson GP; Gross R
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):488-491. PubMed ID: 28481785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
    Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
    Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.
    Olagunju A; Siccardi M; Amara A; Jevtovic D; Kusic J; Owen A; Dragovic G
    Ther Drug Monit; 2014 Dec; 36(6):734-8. PubMed ID: 24831655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.